Logo image of BCART.BR

BIOCARTIS GROUP NV (BCART.BR) Stock Fundamental Analysis

EBR:BCART - Euronext Brussels - BE0974281132 - Common Stock - Currency: EUR

0.29  +0.01 (+1.75%)

Fundamental Rating

2

Overall BCART gets a fundamental rating of 2 out of 10. We evaluated BCART against 58 industry peers in the Health Care Equipment & Supplies industry. BCART has a bad profitability rating. Also its financial health evaluation is rather negative. BCART is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCART had negative earnings in the past year.
In the past year BCART has reported a negative cash flow from operations.
BCART had negative earnings in each of the past 5 years.
In the past 5 years BCART always reported negative operating cash flow.
BCART.BR Yearly Net Income VS EBIT VS OCF VS FCFBCART.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

The profitability ratios for BCART are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCART.BR Yearly ROA, ROE, ROICBCART.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 100 -100 200

1.3 Margins

BCART has a Gross Margin (48.16%) which is comparable to the rest of the industry.
BCART's Gross Margin has declined in the last couple of years.
BCART does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.82%
GM growth 5Y-3.85%
BCART.BR Yearly Profit, Operating, Gross MarginsBCART.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

BCART does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BCART has been increased compared to 1 year ago.
Compared to 1 year ago, BCART has an improved debt to assets ratio.
BCART.BR Yearly Shares OutstandingBCART.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
BCART.BR Yearly Total Debt VS Total AssetsBCART.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -5.89, we must say that BCART is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.89, BCART is not doing good in the industry: 94.44% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.89
ROIC/WACCN/A
WACC5.17%
BCART.BR Yearly LT Debt VS Equity VS FCFBCART.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

BCART has a Current Ratio of 1.65. This is a normal value and indicates that BCART is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.65, BCART perfoms like the industry average, outperforming 42.59% of the companies in the same industry.
A Quick Ratio of 1.20 indicates that BCART should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.20, BCART perfoms like the industry average, outperforming 48.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.2
BCART.BR Yearly Current Assets VS Current LiabilitesBCART.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BCART have decreased by -1.55% in the last year.
BCART shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.08%.
BCART shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.36% yearly.
EPS 1Y (TTM)-1.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.11%
Revenue 1Y (TTM)19.08%
Revenue growth 3Y15.36%
Revenue growth 5Y22.36%
Sales Q2Q%17.8%

3.2 Future

BCART is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.29% yearly.
The Revenue is expected to grow by 21.39% on average over the next years. This is a very strong growth
EPS Next Y36%
EPS Next 2Y31.91%
EPS Next 3Y24.29%
EPS Next 5YN/A
Revenue Next Year3.76%
Revenue Next 2Y16.6%
Revenue Next 3Y21.39%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BCART.BR Yearly Revenue VS EstimatesBCART.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
BCART.BR Yearly EPS VS EstimatesBCART.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BCART reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BCART is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCART.BR Price Earnings VS Forward Price EarningsBCART.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCART.BR Per share dataBCART.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

BCART's earnings are expected to grow with 24.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.91%
EPS Next 3Y24.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCART!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCARTIS GROUP NV

EBR:BCART (9/22/2023, 7:00:00 PM)

0.29

+0.01 (+1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap27.24M
Analysts84.44
Price Target1.12 (286.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-26.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-60%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.47
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.61
BVpS-0.32
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.16%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.82%
GM growth 5Y-3.85%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.48%
Cap/Sales 3.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.2
Altman-Z -5.89
F-Score4
WACC5.17%
ROIC/WACCN/A
Cap/Depr(3y)29.2%
Cap/Depr(5y)49.97%
Cap/Sales(3y)6.05%
Cap/Sales(5y)9.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.11%
EPS Next Y36%
EPS Next 2Y31.91%
EPS Next 3Y24.29%
EPS Next 5YN/A
Revenue 1Y (TTM)19.08%
Revenue growth 3Y15.36%
Revenue growth 5Y22.36%
Sales Q2Q%17.8%
Revenue Next Year3.76%
Revenue Next 2Y16.6%
Revenue Next 3Y21.39%
Revenue Next 5YN/A
EBIT growth 1Y24.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.9%
EBIT Next 3Y29.4%
EBIT Next 5YN/A
FCF growth 1Y32.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.74%
OCF growth 3YN/A
OCF growth 5YN/A